FDA Approves LYBALVI — Alkermes, Inc.

# FDA Approves Alkermes' LYBALVI for Schizophrenia and Bipolar Disorder Treatment Alkermes, Inc. received FDA approval for LYBALVI (olanzapine and samidorphan), a novel oral combination therapy designed to address weight gain associated with antipsychotic treatment, positioning the company to capture market share in the competitive schizophrenia and bipolar disorder segment. The approval of this first-in-class fixed-dose combination could drive significant revenue growth for Alkermes while offering clinicians an important new option to improve patient adherence